BAX protein expression and clinical outcome in epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2583-2590

  Tai, Yu Tzu ^a   Lee, Sandra ^a   Niloff, Eric ^a   Weisman, Carlo ^a   Strobel, Thomas ^a   Cannistra, Stephen A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELL PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PROTEIN BAX; VINCRISTINE;

ADULT; ARTICLE; BREAST EPITHELIUM; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0031927982     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2583     Document Type: Article

References (44)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
2. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
4. Bookman MA, McGuire WP, Kilpatrick D, et al: Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902, 1996
5. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386-401, 1996
6. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
7. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994
8. Reed JC: Bcl-2 family proteins: Regulators of chemoresistance in cancer. Toxicol Lett 83:155-158, 1995
9. Tang C, Willingham MC, Reed JC, et al: High levels of p26BCL-2 oncoprotein retard Taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1969, 1994
10. Yin DX, Schimke RT: BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res 55:4922-4928, 1995
11. Datta R, Manome Y, Taneja N, et al: Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 6:363-370, 1995
12. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 79:189-192, 1994
13. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993
14. Strobel T, Swanson L, Korsmeyer S, et al: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93:14094-14099, 1996
15. Strobel T, Swanson L, Korsmeyer S, et al: Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene 14:2753-2758, 1997
16. Cannistra SA, Kansas GS, Niloff J, et al: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 53:3830-3838, 1993
17. Bast RC, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337, 1981
18. Cannistra SA, Ottensmeier C, Niloff J, et al: Expression and function of beta 1 and alpha ν beta 3 integrins in ovarian cancer. Gynecol Oncol 58:216-225, 1995
19. Cannistra SA, DeFranzo B, Niloff J, et al: Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1:333-342, 1995
20. Cannistra SA, Abu-Jawdeh G, Niloff J, et al: CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors. J Clin Oncol 13:1912-1921, 1995
21. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467, 1977
22. Cox DR, Snell EJ: the Analysis of Binary Data. New York, NY, Chapman & Hall, 1989
23. Lehmann EL: Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA, Holden Day, 1975
24. Kaplan EL, Meier R: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-581, 1958
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
26. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
27. McCurrach ME, Connor TM, Knudson CM, et al: Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 94:2345-2349, 1997
28. Dembo AJ: Controversy over combination chemotherapy in advanced ovarian cancer: What we learn from reports of matured data. J Clin Oncol 4:1573-1576, 1986
29. Miyashita T, Krajewski S, Krajewska M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805, 1994
30. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
31. Kupryjanczyk J, Thor AD, Beauchamp R, et al: p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 90:4961-4965, 1993
32. Krajewski S, Blomqvist C, Franssila K, et al: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55:4471-4478, 1995
33. Marx D, Binder C, Meden H, et al: Differential expression of apoptosis-associated genes bax and bcl-2 in ovarian cancer. Anticancer Res 17:2233-2240, 1997
34. Krajewski S, Thor AD, Edgerton SM, et al: Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 3:199-208, 1997
35. Herod JJ, Eliopoulos AG, Warwick J, et al: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184, 1996
36. Gasparini G, Barbareschi M, Doglioni C, et al: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1:189-198, 1995
37. Pezzella F, Turley H, Kuzu I, et al: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690-694, 1993
38. Silvestrini R, Benini E, Veneroni S, et al: p53 and Bcl-2 expression correlates with clinical outcome in a series of node- positive breast cancer patients. J Clin Oncol 14:1604-1610, 1996
39. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto- oncogene expression in human breast cancer cells. Cancer Res 55:3902-3907, 1995
40. Huang Y, Ray S, Reed JC, et al: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits Taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:73-81, 1997
41. Brady HJ, Gil-Gomez G, Kirberg J, et al: Bax-alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J 15:6991-7001, 1996
42. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997
43. Meijerink JP, Smetsers TF, Sloetjes AW, et al: Bax mutations in cell lines derived from hematological malignancies. Leukemia 9:1828-1832, 1995
44. Yin C, Knudson CM, Korsmeyer SJ, et al: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640, 1997